Jeff Burkhardt serves as the Business Development Director at Labcorp, where he plays a pivotal role in driving preclinical drug development initiatives and IND (Investigational New Drug) enabling programs across the Southeast. With a deep-rooted passion for advancing drug therapies and improving patient outcomes, Jeff...
Jeff Burkhardt serves as the Business Development Director at Labcorp, where he plays a pivotal role in driving preclinical drug development initiatives and IND (Investigational New Drug) enabling programs across the Southeast. With a deep-rooted passion for advancing drug therapies and improving patient outcomes, Jeff is dedicated to bridging the gap between innovative science and its practical application in the pharmaceutical industry. His expertise spans a wide array of critical areas, including safety assessment, dose range finding (DRF), toxicology, and genetic toxicology, making him a valuable asset in the biopharmaceutical landscape.
In his current role, Jeff directs strategic business development activities that not only support the advancement of drug therapies but also foster collaborations with key stakeholders in the industry. He is particularly focused on enhancing the efficiency of drug development processes, ensuring that therapies reach patients in a timely manner. His extensive knowledge in safety pharmacology, chronic toxicology, and carcinogenicity equips him to navigate complex regulatory landscapes and facilitate successful IND submissions.
Jeff’s proficiency in CRO (Contract Research Organization) management and his adeptness with tools like Salesforce.com enable him to streamline operations and enhance client relationships. His commitment to excellence in method development and validation further underscores his role in ensuring that Labcorp remains at the forefront of drug development. Through his leadership, Jeff is not only advancing Labcorp's mission but also contributing significantly to the broader goal of improving lives through innovative healthcare solutions.
